Qualifying Conditions for Medical Cannabis in the UK

Medical cannabis is not an ordinary prescription route in the UK. The practical question is not just "what condition do you have?", but whether there is a recognised cannabis-based medicine, specialist oversight, and enough evidence to justify it for your situation.

Key takeaways

• There is no single universal qualifying list for medical cannabis in the UK.
• On the NHS, cannabis-based medicine is only likely to be prescribed for a small number of patients.
• NICE only supports limited use in specific situations: certain severe treatment-resistant epilepsies, moderate to severe MS spasticity, and chemotherapy-induced nausea and vomiting that has not responded to usual anti-sickness treatment.
• NICE advises against offering CBD, THC, nabilone, dronabinol, or CBD+THC combinations for chronic pain in adults outside a clinical trial.
• Private pathways may look broader, but they do not remove the need for specialist oversight, monitoring, and a realistic evidence check.

Evidence base

The NHS says medical cannabis can only be prescribed on the NHS by a specialist hospital doctor, or under a specialist's supervision, and it is only likely to be prescribed for a small number of patients. NHS England adds that the evidence base is still developing and that long-term harms have not been well studied.

NICE NG144 sets the clearest boundaries:

• for chemotherapy-induced nausea and vomiting, nabilone may be considered as an add-on when standard anti-sickness medicines have not worked
• for MS spasticity, a 4-week trial of THC:CBD spray may be offered in adults if other treatments have not helped
• for severe treatment-resistant epilepsy, cannabidiol is recommended only in certain licensed or technology-appraisal-backed situations
• for chronic pain, NICE says not to offer CBD, THC, nabilone, dronabinol, or CBD+THC combinations outside research

That means the evidence is condition-specific. A treatment that may be reasonable in one setting is not automatically suitable in another.

What patients should know

If you are trying to work out whether you qualify, start with the condition, the symptom, and the treatment history. In practice, the key questions are:

• have standard treatments already been tried?
• is there a specialist with the right expertise to review the case?
• is the product licensed, or is it an unlicensed cannabis-based medicinal product?
• how will benefit, side effects, and stopping rules be monitored?

There is no simple all-purpose list that applies to every clinic. NHS access is narrow. Private clinics can operate differently, and private doctors on the GMC specialist register may prescribe cannabis-based products for medicinal use, but they should still follow equivalent specialist processes and governance. That is not the same as saying the evidence is strong enough for broad use.

It is also worth separating prescription medicines from online or shop-bought products. The NHS warns that many products sold online have unknown quality and content, and some CBD oils sold as supplements are not the same thing as a medicinal product.

When to speak to a clinician

Speak to a clinician if:

• you think you may fit one of the narrow NHS indications
• you are being offered a private prescription and want help weighing the evidence
• your current treatment is not helping and you want to discuss specialist referral options
• you are pregnant, breastfeeding, or planning pregnancy
• you have a history of psychosis, mood disorder, substance misuse, liver disease, renal disease, or cardiovascular disease
• you want to check whether a product is medicine, supplement, or something you should avoid

If you are looking for a qualifying list, ask for the evidence behind the recommendation rather than the brand name alone.

Source trail

• NHS medical cannabis page: access is specialist-led and likely to apply to only a small number of patients.
• NHS England CBPMs: the evidence base is still developing; long-term harms are not well studied; private specialist prescribing is possible but still governed.
• NICE NG144: narrow recommendations for nausea/vomiting, MS spasticity, and severe treatment-resistant epilepsy; not recommended for chronic pain outside trials.
• MHRA CBD statement: CBD products making medicinal claims are medicines and must meet medicinal standards.